SGHT vs. DCTH, CLPT, SMLR, NNOX, TCMD, NPCE, ZIMV, CVRX, NYXH, and SMTI
Should you be buying Sight Sciences stock or one of its competitors? The main competitors of Sight Sciences include Delcath Systems (DCTH), ClearPoint Neuro (CLPT), Semler Scientific (SMLR), Nano-X Imaging (NNOX), Tactile Systems Technology (TCMD), NeuroPace (NPCE), ZimVie (ZIMV), CVRx (CVRX), Nyxoah (NYXH), and Sanara MedTech (SMTI). These companies are all part of the "medical equipment" industry.
Sight Sciences vs.
Delcath Systems (NASDAQ:DCTH) and Sight Sciences (NASDAQ:SGHT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, earnings, community ranking, analyst recommendations, valuation and institutional ownership.
Delcath Systems has higher earnings, but lower revenue than Sight Sciences. Delcath Systems is trading at a lower price-to-earnings ratio than Sight Sciences, indicating that it is currently the more affordable of the two stocks.
61.1% of Delcath Systems shares are owned by institutional investors. Comparatively, 55.5% of Sight Sciences shares are owned by institutional investors. 17.9% of Delcath Systems shares are owned by insiders. Comparatively, 28.9% of Sight Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
In the previous week, Sight Sciences had 1 more articles in the media than Delcath Systems. MarketBeat recorded 3 mentions for Sight Sciences and 2 mentions for Delcath Systems. Delcath Systems' average media sentiment score of 0.92 beat Sight Sciences' score of 0.51 indicating that Delcath Systems is being referred to more favorably in the media.
Delcath Systems received 13 more outperform votes than Sight Sciences when rated by MarketBeat users. However, 31.15% of users gave Sight Sciences an outperform vote while only 26.89% of users gave Delcath Systems an outperform vote.
Sight Sciences has a net margin of -63.30% compared to Delcath Systems' net margin of -150.70%. Sight Sciences' return on equity of -47.28% beat Delcath Systems' return on equity.
Delcath Systems presently has a consensus price target of $22.25, suggesting a potential upside of 49.53%. Sight Sciences has a consensus price target of $4.68, suggesting a potential upside of 85.11%. Given Sight Sciences' higher possible upside, analysts clearly believe Sight Sciences is more favorable than Delcath Systems.
Delcath Systems has a beta of 0.86, indicating that its share price is 14% less volatile than the S&P 500. Comparatively, Sight Sciences has a beta of 2.52, indicating that its share price is 152% more volatile than the S&P 500.
Summary
Sight Sciences beats Delcath Systems on 11 of the 18 factors compared between the two stocks.
Get Sight Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for SGHT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sight Sciences Competitors List
Related Companies and Tools
This page (NASDAQ:SGHT) was last updated on 2/22/2025 by MarketBeat.com Staff
Free SGHT Stock Alerts